An open label study, to evaluate the pharmacokinetics, safety and toleration Of a single oral dose of Pf-00868554 in subjects with hepatic impairment to subjects with normal hepatic function.

Trial Profile

An open label study, to evaluate the pharmacokinetics, safety and toleration Of a single oral dose of Pf-00868554 in subjects with hepatic impairment to subjects with normal hepatic function.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Filibuvir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Nov 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
    • 14 Oct 2008 Actual start date changed from Feb 2008 to Mar 2008 as reported by ClinicalTrials.gov.
    • 14 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top